Coherus Oncology, Inc. business relationships
Companies named in Coherus Oncology, Inc.’s 10-K filed 2026-03-09, and public companies whose annual reports name Coherus Oncology, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Coherus Oncology, Inc.’s annual report 8
“...strative expenses in the consolidated statements of operations relating to the write-off of the net carrying value of the Novartis Institutes out-license intangible asset of $ 10.6 million and the final remeasurement of the CVR liability related to NZV930 of $ 3.8 million to its fair value of zero .” SEC filing
“Settlement and License Agreements with Pfizer” SEC filing
“During the year ended December 31, 2025, approximately 99% of LOQTORZI revenues were from three large wholesale distributors: McKesson Corporation , Cencora, Inc., and Cardinal Health, Inc.” SEC filing
“During the year ended December 31, 2025, approximately 99% of LOQTORZI revenues were from three large wholesale distributors: McKesson Corporation , Cencora, Inc., and Cardinal Health, Inc.” SEC filing
“GSK Out-licensing Agreement” SEC filing
“License Agreement, dated as of December 16, 2020, by and between Surface Oncology, Inc. and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED.” SEC filing
“During the year ended December 31, 2025, approximately 99% of LOQTORZI revenues were from three large wholesale distributors: McKesson Corporation , Cencora, Inc., and Cardinal Health, Inc.” SEC filing
“License Agreement with Vaccinex” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.